Skip to content 
AMM 190: The PRF Controversy Unpacked: Insights From Top Dermatologists
September 03, 2024
This episode, dated September 3, 2024, delves into the latest developments and controversies surrounding Platelet-Rich Fibrin (PRF) in dermatology. Expert dermatologists Dr. Doris Day and Dr. Ava Shamban discuss the skepticism and emerging interest in PRF as an alternative to traditional fillers. They highlight concerns about its effectiveness and safety, contrasting it with established treatments like hyaluronic acid fillers. The FDA’s stance on PRF, including contamination risks and the absence of formal approval, is also examined. Listeners will gain a nuanced understanding of PRF’s potential and limitations in skin rejuvenation.
Quick Takes
- Dr. Doris Day advises against using PRF for skin rejuvenation due to lack of solid data and potential scarring.
- Dr. Ava Shamban explains the growing interest in PRF as a filler due to “filler fatigue,” but notes its limitations compared to hyaluronic acid fillers.
- The FDA classifies PRF as a tissue transfer, expressing concerns about contamination and safety, with no approved treatments yet.
Episode Transcript
Today is September 3, 2024, and we’re diving into the latest buzz around Platelet-Rich Fibrin (PRF) as a filler. Despite its rising popularity, many experts remain skeptical. Dr. Doris Day, a highly regarded dermatologist, cautions against using PRF for skin rejuvenation, noting a lack of solid data and even scarring in some cases. She points out that PRF, often marketed as a filler, doesn’t function like traditional fillers.
Dr. Ava Shamban, a board-certified dermatologist in Beverly Hills and Santa Monica, sheds light on why PRF is gaining interest. We’re experiencing “filler fatigue,” where overfilled faces lead patients to seek more natural alternatives. However, even Dr. Shamban acknowledges that while PRF can be promising, it falls short of the volumizing power of hyaluronic acid fillers.
The FDA has also weighed in, treating PRF like a tissue transfer and highlighting concerns about contamination. A past incident in New Mexico, where PRP facials led to HIV infections, emphasizes the need for caution. The FDA has not approved PRF treatments for any condition yet, stressing the necessity for thorough evaluations.
Stay tuned for more updates on this evolving field.
